| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Membrane Glycoproteins | 41 | 2024 | 65 | 10.210 |
Why?
|
| Endometrial Neoplasms | 9 | 2021 | 25 | 3.230 |
Why?
|
| Neovascularization, Pathologic | 9 | 2024 | 23 | 2.970 |
Why?
|
| Biomarkers, Tumor | 8 | 2026 | 51 | 2.800 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2021 | 88 | 2.590 |
Why?
|
| Animals | 41 | 2026 | 1875 | 2.240 |
Why?
|
| Mice | 33 | 2026 | 746 | 2.210 |
Why?
|
| Brain Neoplasms | 5 | 2026 | 11 | 2.190 |
Why?
|
| Glioblastoma | 4 | 2024 | 4 | 1.930 |
Why?
|
| Breast Neoplasms | 4 | 2024 | 170 | 1.840 |
Why?
|
| Precancerous Conditions | 6 | 2021 | 12 | 1.750 |
Why?
|
| Female | 35 | 2026 | 4060 | 1.720 |
Why?
|
| Vascular Endothelial Growth Factor A | 8 | 2024 | 30 | 1.710 |
Why?
|
| Humans | 50 | 2026 | 6794 | 1.680 |
Why?
|
| Cell Line, Tumor | 15 | 2024 | 156 | 1.590 |
Why?
|
| Neoplasms | 3 | 2024 | 92 | 1.580 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2026 | 10 | 1.360 |
Why?
|
| Fetal Growth Retardation | 4 | 2019 | 42 | 1.340 |
Why?
|
| Antibodies, Monoclonal | 5 | 2024 | 31 | 1.300 |
Why?
|
| Membrane Proteins | 8 | 2023 | 48 | 1.250 |
Why?
|
| Positron-Emission Tomography | 2 | 2024 | 9 | 1.250 |
Why?
|
| Placenta | 6 | 2024 | 58 | 1.240 |
Why?
|
| Macrophages | 2 | 2021 | 40 | 1.240 |
Why?
|
| Neoplastic Stem Cells | 2 | 2020 | 24 | 1.160 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2024 | 38 | 1.160 |
Why?
|
| Oxygen | 5 | 2026 | 44 | 1.040 |
Why?
|
| Endometrium | 4 | 2012 | 24 | 0.940 |
Why?
|
| Antineoplastic Agents | 6 | 2024 | 72 | 0.910 |
Why?
|
| Endothelial Cells | 2 | 2024 | 17 | 0.900 |
Why?
|
| Granzymes | 1 | 2024 | 1 | 0.890 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2024 | 10 | 0.890 |
Why?
|
| Zirconium | 1 | 2024 | 1 | 0.860 |
Why?
|
| Radioisotopes | 1 | 2024 | 2 | 0.860 |
Why?
|
| Focal Adhesion Kinase 1 | 7 | 2015 | 8 | 0.830 |
Why?
|
| src-Family Kinases | 4 | 2014 | 7 | 0.810 |
Why?
|
| Endometrial Hyperplasia | 2 | 2021 | 2 | 0.790 |
Why?
|
| Signal Transduction | 8 | 2024 | 246 | 0.760 |
Why?
|
| Immunoglobulin G | 3 | 2017 | 19 | 0.760 |
Why?
|
| Cell Proliferation | 6 | 2024 | 143 | 0.740 |
Why?
|
| Mice, Nude | 7 | 2024 | 41 | 0.730 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 35 | 0.720 |
Why?
|
| Histocompatibility, Maternal-Fetal | 1 | 2021 | 1 | 0.690 |
Why?
|
| Decidua | 1 | 2021 | 2 | 0.690 |
Why?
|
| Mice, Inbred BALB C | 9 | 2020 | 46 | 0.680 |
Why?
|
| Molecular Targeted Therapy | 4 | 2017 | 12 | 0.670 |
Why?
|
| Retinal Pigment Epithelium | 7 | 2022 | 8 | 0.660 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 25 | 0.640 |
Why?
|
| Disease Models, Animal | 7 | 2026 | 231 | 0.630 |
Why?
|
| Retinopathy of Prematurity | 3 | 2026 | 3 | 0.620 |
Why?
|
| Retinal Neovascularization | 3 | 2026 | 3 | 0.620 |
Why?
|
| Adenocarcinoma | 3 | 2012 | 50 | 0.610 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2019 | 2 | 0.600 |
Why?
|
| Pregnancy | 8 | 2024 | 599 | 0.580 |
Why?
|
| Prognosis | 5 | 2026 | 220 | 0.550 |
Why?
|
| Myelin Proteins | 3 | 2015 | 4 | 0.550 |
Why?
|
| Retinal Dehydrogenase | 1 | 2017 | 3 | 0.530 |
Why?
|
| Isoenzymes | 1 | 2017 | 15 | 0.530 |
Why?
|
| Hypoxia | 4 | 2022 | 37 | 0.530 |
Why?
|
| Placental Insufficiency | 1 | 2017 | 1 | 0.530 |
Why?
|
| Tetraspanins | 2 | 2015 | 2 | 0.510 |
Why?
|
| Mice, Inbred C57BL | 9 | 2026 | 258 | 0.480 |
Why?
|
| Tissue Distribution | 4 | 2024 | 27 | 0.470 |
Why?
|
| Apoptosis | 6 | 2024 | 179 | 0.460 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2026 | 6 | 0.460 |
Why?
|
| Gene Expression Profiling | 5 | 2019 | 44 | 0.440 |
Why?
|
| Air Pollutants | 2 | 2024 | 6 | 0.430 |
Why?
|
| Tissue Array Analysis | 5 | 2017 | 5 | 0.430 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 6 | 0.420 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 45 | 0.400 |
Why?
|
| Immunoglobulin Fragments | 3 | 2012 | 3 | 0.400 |
Why?
|
| Adult | 6 | 2021 | 2113 | 0.390 |
Why?
|
| Molecular Imaging | 1 | 2013 | 1 | 0.390 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2013 | 2 | 0.390 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2013 | 4 | 0.370 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 3 | 2022 | 5 | 0.360 |
Why?
|
| RNA, Messenger | 8 | 2020 | 190 | 0.360 |
Why?
|
| Protein Binding | 5 | 2011 | 29 | 0.350 |
Why?
|
| Cell Movement | 7 | 2019 | 38 | 0.350 |
Why?
|
| Membrane Microdomains | 3 | 2011 | 4 | 0.350 |
Why?
|
| Integrin alpha6 | 1 | 2011 | 2 | 0.350 |
Why?
|
| Eukaryotic Initiation Factor-3 | 1 | 2010 | 1 | 0.330 |
Why?
|
| Middle Aged | 7 | 2021 | 2108 | 0.330 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 35 | 0.320 |
Why?
|
| Cell Adhesion | 4 | 2011 | 19 | 0.310 |
Why?
|
| Aged | 5 | 2021 | 1539 | 0.310 |
Why?
|
| Blotting, Western | 9 | 2019 | 110 | 0.310 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 497 | 0.310 |
Why?
|
| Embryo Implantation | 2 | 2006 | 8 | 0.300 |
Why?
|
| Immunohistochemistry | 5 | 2017 | 118 | 0.290 |
Why?
|
| Neoplasms, Experimental | 1 | 2008 | 9 | 0.290 |
Why?
|
| Progesterone | 1 | 2008 | 14 | 0.280 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2020 | 8 | 0.280 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 90 | 0.280 |
Why?
|
| Estradiol | 1 | 2008 | 57 | 0.270 |
Why?
|
| Epithelial Cells | 5 | 2019 | 49 | 0.270 |
Why?
|
| Disease Progression | 4 | 2024 | 170 | 0.270 |
Why?
|
| Corneal Neovascularization | 2 | 2019 | 2 | 0.250 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2026 | 4 | 0.240 |
Why?
|
| Microglia | 1 | 2026 | 5 | 0.240 |
Why?
|
| Antibodies, Blocking | 2 | 2019 | 2 | 0.240 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2026 | 3 | 0.240 |
Why?
|
| Flow Cytometry | 6 | 2014 | 48 | 0.240 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2005 | 1 | 0.240 |
Why?
|
| Cell Line | 9 | 2020 | 124 | 0.230 |
Why?
|
| Immunotherapy | 2 | 2019 | 16 | 0.230 |
Why?
|
| Caveolins | 2 | 2004 | 2 | 0.220 |
Why?
|
| Melanoma | 2 | 2016 | 14 | 0.220 |
Why?
|
| Infant, Newborn | 2 | 2022 | 199 | 0.220 |
Why?
|
| Skin Neoplasms | 2 | 2016 | 21 | 0.220 |
Why?
|
| Honey | 1 | 2024 | 2 | 0.220 |
Why?
|
| Glycosylphosphatidylinositols | 1 | 2004 | 1 | 0.210 |
Why?
|
| Enzyme Activation | 3 | 2014 | 39 | 0.210 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 36 | 0.210 |
Why?
|
| Phenotype | 3 | 2024 | 91 | 0.210 |
Why?
|
| Collagen Type I | 4 | 2012 | 18 | 0.200 |
Why?
|
| Gene Expression Regulation | 5 | 2019 | 120 | 0.200 |
Why?
|
| Immune Tolerance | 2 | 2021 | 8 | 0.200 |
Why?
|
| Mice, Knockout | 2 | 2021 | 150 | 0.200 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2020 | 15 | 0.200 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2003 | 7 | 0.200 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2003 | 10 | 0.200 |
Why?
|
| Eye | 1 | 2003 | 14 | 0.200 |
Why?
|
| Extracellular Vesicles | 1 | 2023 | 6 | 0.190 |
Why?
|
| Retinal Pigments | 1 | 2022 | 1 | 0.190 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 22 | 0.190 |
Why?
|
| Transfection | 2 | 2017 | 56 | 0.190 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 34 | 0.190 |
Why?
|
| Integrin alpha6beta1 | 1 | 2002 | 1 | 0.190 |
Why?
|
| Transcriptome | 2 | 2019 | 31 | 0.190 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 63 | 0.180 |
Why?
|
| Pigment Epithelium of Eye | 3 | 2007 | 5 | 0.180 |
Why?
|
| Palatine Tonsil | 1 | 2002 | 1 | 0.180 |
Why?
|
| Cytological Techniques | 1 | 2002 | 2 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 72 | 0.180 |
Why?
|
| Retina | 3 | 2026 | 29 | 0.180 |
Why?
|
| Phosphorylation | 4 | 2024 | 73 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 42 | 0.170 |
Why?
|
| Models, Animal | 1 | 2021 | 23 | 0.170 |
Why?
|
| Immunity, Innate | 1 | 2021 | 20 | 0.170 |
Why?
|
| Antigens, CD34 | 2 | 2019 | 3 | 0.170 |
Why?
|
| Immunoprecipitation | 3 | 2011 | 12 | 0.160 |
Why?
|
| Green Fluorescent Proteins | 2 | 2017 | 7 | 0.160 |
Why?
|
| Protein Transport | 3 | 2011 | 23 | 0.160 |
Why?
|
| Trophoblasts | 2 | 2017 | 8 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2019 | 35 | 0.160 |
Why?
|
| Meningeal Neoplasms | 1 | 2020 | 1 | 0.160 |
Why?
|
| Meningioma | 1 | 2020 | 1 | 0.160 |
Why?
|
| Tetralogy of Fallot | 1 | 2019 | 1 | 0.160 |
Why?
|
| Heart Ventricles | 1 | 2019 | 15 | 0.160 |
Why?
|
| Male | 5 | 2020 | 3671 | 0.160 |
Why?
|
| Vitreoretinopathy, Proliferative | 2 | 2011 | 2 | 0.160 |
Why?
|
| Protein Isoforms | 1 | 2019 | 12 | 0.150 |
Why?
|
| RNA, Small Interfering | 2 | 2017 | 26 | 0.150 |
Why?
|
| Animals, Newborn | 3 | 2026 | 112 | 0.150 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 34 | 0.150 |
Why?
|
| Limbus Corneae | 2 | 2019 | 5 | 0.140 |
Why?
|
| Up-Regulation | 2 | 2020 | 94 | 0.140 |
Why?
|
| Chlamydia muridarum | 2 | 2009 | 2 | 0.140 |
Why?
|
| Glioma | 1 | 2017 | 3 | 0.130 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2019 | 93 | 0.130 |
Why?
|
| Caveolin 1 | 3 | 2007 | 4 | 0.130 |
Why?
|
| Microarray Analysis | 1 | 2017 | 5 | 0.130 |
Why?
|
| Homologous Recombination | 1 | 2017 | 1 | 0.130 |
Why?
|
| Fibrin | 1 | 2017 | 5 | 0.130 |
Why?
|
| Mice, SCID | 1 | 2017 | 16 | 0.130 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 4 | 0.130 |
Why?
|
| Pericytes | 2 | 2016 | 2 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2017 | 11 | 0.130 |
Why?
|
| Uterus | 1 | 2017 | 15 | 0.130 |
Why?
|
| Placentation | 1 | 2017 | 12 | 0.130 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 172 | 0.130 |
Why?
|
| Interleukin-10 | 1 | 2016 | 10 | 0.120 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2016 | 10 | 0.120 |
Why?
|
| Fetal Nutrition Disorders | 1 | 2016 | 9 | 0.120 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2016 | 16 | 0.120 |
Why?
|
| Retrospective Studies | 2 | 2011 | 681 | 0.120 |
Why?
|
| Autophagy | 1 | 2016 | 29 | 0.120 |
Why?
|
| Microcirculation | 1 | 2016 | 14 | 0.120 |
Why?
|
| Gene Expression | 2 | 2017 | 77 | 0.110 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 29 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 18 | 0.110 |
Why?
|
| 3T3 Cells | 3 | 2003 | 12 | 0.110 |
Why?
|
| Maternal Exposure | 2 | 2024 | 17 | 0.110 |
Why?
|
| Peroxynitrous Acid | 1 | 2014 | 2 | 0.110 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2014 | 4 | 0.110 |
Why?
|
| DNA Methylation | 2 | 2024 | 26 | 0.110 |
Why?
|
| Integrins | 2 | 2011 | 4 | 0.100 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2014 | 3 | 0.100 |
Why?
|
| Extracellular Matrix | 2 | 2005 | 22 | 0.100 |
Why?
|
| Molecular Mimicry | 1 | 2013 | 1 | 0.100 |
Why?
|
| Copper Radioisotopes | 1 | 2013 | 1 | 0.100 |
Why?
|
| Protein Engineering | 1 | 2013 | 1 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2013 | 63 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2013 | 95 | 0.100 |
Why?
|
| Microscopy, Confocal | 3 | 2012 | 11 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 17 | 0.090 |
Why?
|
| Hyperoxia | 2 | 2024 | 18 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2012 | 53 | 0.090 |
Why?
|
| Validation Studies as Topic | 1 | 2011 | 1 | 0.090 |
Why?
|
| Wound Healing | 1 | 2011 | 14 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2011 | 19 | 0.090 |
Why?
|
| Menstrual Cycle | 1 | 2011 | 11 | 0.090 |
Why?
|
| Lymphoma, B-Cell | 2 | 2001 | 2 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2019 | 234 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2024 | 27 | 0.080 |
Why?
|
| Cell Membrane | 2 | 2007 | 54 | 0.070 |
Why?
|
| Immunoglobulins | 1 | 2009 | 5 | 0.070 |
Why?
|
| Genital Diseases, Female | 1 | 2009 | 3 | 0.070 |
Why?
|
| Chlamydia Infections | 1 | 2009 | 8 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 2 | 2006 | 25 | 0.070 |
Why?
|
| Antibody Specificity | 1 | 2008 | 5 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 7 | 0.070 |
Why?
|
| RNA | 2 | 2014 | 25 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 24 | 0.070 |
Why?
|
| In Vitro Techniques | 1 | 2008 | 72 | 0.070 |
Why?
|
| NIH 3T3 Cells | 2 | 2007 | 5 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2007 | 57 | 0.070 |
Why?
|
| Collagen | 1 | 2007 | 31 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2007 | 20 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 40 | 0.070 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 24 | 0.060 |
Why?
|
| Fatty Acid Desaturases | 1 | 2026 | 1 | 0.060 |
Why?
|
| RNA, Catalytic | 1 | 2006 | 1 | 0.060 |
Why?
|
| Blastocyst | 1 | 2006 | 5 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2006 | 89 | 0.060 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 21 | 0.060 |
Why?
|
| Survival Rate | 1 | 2006 | 111 | 0.060 |
Why?
|
| Mice, Transgenic | 1 | 2026 | 59 | 0.060 |
Why?
|
| Epithelium | 1 | 2005 | 22 | 0.060 |
Why?
|
| Fibronectins | 1 | 2005 | 18 | 0.060 |
Why?
|
| Leptospermum | 1 | 2024 | 2 | 0.050 |
Why?
|
| 5-Methylcytosine | 1 | 2024 | 2 | 0.050 |
Why?
|
| Intravitreal Injections | 1 | 2024 | 6 | 0.050 |
Why?
|
| MCF-7 Cells | 1 | 2024 | 15 | 0.050 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2024 | 14 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2024 | 16 | 0.050 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2024 | 28 | 0.050 |
Why?
|
| Adaptor Protein Complex gamma Subunits | 1 | 2004 | 1 | 0.050 |
Why?
|
| beta-Cyclodextrins | 1 | 2004 | 1 | 0.050 |
Why?
|
| Caveolin 2 | 1 | 2004 | 1 | 0.050 |
Why?
|
| Retroviridae | 1 | 2004 | 2 | 0.050 |
Why?
|
| Golgi Apparatus | 1 | 2004 | 2 | 0.050 |
Why?
|
| Fetal Development | 1 | 2024 | 28 | 0.050 |
Why?
|
| Molecular Chaperones | 1 | 2004 | 7 | 0.050 |
Why?
|
| Transferrin | 1 | 2004 | 9 | 0.050 |
Why?
|
| Heat-Shock Proteins | 1 | 2004 | 9 | 0.050 |
Why?
|
| Pulmonary Alveoli | 1 | 2004 | 33 | 0.050 |
Why?
|
| Insulin Resistance | 1 | 2024 | 74 | 0.050 |
Why?
|
| Fetus | 1 | 2024 | 125 | 0.050 |
Why?
|
| G(M1) Ganglioside | 1 | 2003 | 1 | 0.050 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2003 | 1 | 0.050 |
Why?
|
| Immunoblotting | 1 | 2003 | 16 | 0.050 |
Why?
|
| Cell Communication | 1 | 2003 | 11 | 0.050 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2003 | 2 | 0.050 |
Why?
|
| Iris | 1 | 2003 | 5 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 9 | 0.050 |
Why?
|
| Sclera | 1 | 2003 | 7 | 0.050 |
Why?
|
| Cornea | 1 | 2003 | 13 | 0.050 |
Why?
|
| Antibodies | 1 | 2003 | 16 | 0.050 |
Why?
|
| Optic Nerve | 1 | 2003 | 12 | 0.050 |
Why?
|
| Glypicans | 1 | 2023 | 2 | 0.050 |
Why?
|
| Ciliary Body | 1 | 2003 | 10 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2002 | 4 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2023 | 36 | 0.050 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Micromanipulation | 1 | 2002 | 1 | 0.050 |
Why?
|
| Lasers | 1 | 2002 | 11 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2002 | 6 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2002 | 10 | 0.050 |
Why?
|
| Inflammation | 2 | 2016 | 143 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 98 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2012 | 8 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2016 | 18 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2000 | 18 | 0.040 |
Why?
|
| Drosophila Proteins | 1 | 2000 | 9 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2000 | 22 | 0.040 |
Why?
|
| Retinal Vessels | 1 | 2020 | 12 | 0.040 |
Why?
|
| E2F1 Transcription Factor | 1 | 2019 | 1 | 0.040 |
Why?
|
| Genome | 1 | 2019 | 7 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 8 | 0.040 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2019 | 13 | 0.040 |
Why?
|
| Wnt Proteins | 1 | 2019 | 15 | 0.040 |
Why?
|
| Infant | 1 | 2019 | 187 | 0.040 |
Why?
|
| Eye Burns | 1 | 2019 | 1 | 0.040 |
Why?
|
| Sodium Hydroxide | 1 | 2019 | 1 | 0.040 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2019 | 258 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2019 | 20 | 0.040 |
Why?
|
| Burns, Chemical | 1 | 2019 | 4 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2019 | 285 | 0.040 |
Why?
|
| Child | 1 | 2019 | 524 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 1 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 45 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 8 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 3 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2016 | 3 | 0.030 |
Why?
|
| Energy Intake | 1 | 2016 | 30 | 0.030 |
Why?
|
| Mothers | 1 | 2016 | 17 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 1 | 2016 | 1 | 0.030 |
Why?
|
| Lectins | 1 | 2016 | 3 | 0.030 |
Why?
|
| Luminescent Proteins | 1 | 2016 | 2 | 0.030 |
Why?
|
| Eating | 1 | 2016 | 31 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 70 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 14 | 0.030 |
Why?
|
| Neural Crest | 1 | 2013 | 4 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 17 | 0.020 |
Why?
|
| Camptothecin | 1 | 2012 | 1 | 0.020 |
Why?
|
| Peptide Library | 1 | 2012 | 1 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2012 | 2 | 0.020 |
Why?
|
| Single-Chain Antibodies | 1 | 2012 | 2 | 0.020 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2012 | 3 | 0.020 |
Why?
|
| Menarche | 1 | 2012 | 3 | 0.020 |
Why?
|
| Menopause | 1 | 2012 | 4 | 0.020 |
Why?
|
| Collagen Type IV | 1 | 2011 | 4 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 193 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 64 | 0.020 |
Why?
|
| Risk Factors | 1 | 2012 | 767 | 0.020 |
Why?
|
| Actins | 1 | 2009 | 28 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2009 | 3 | 0.020 |
Why?
|
| Cytokines | 1 | 2009 | 80 | 0.020 |
Why?
|
| Integrin alpha2 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Integrin alpha1 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 14 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2008 | 17 | 0.020 |
Why?
|
| Indoles | 1 | 2008 | 11 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2008 | 17 | 0.020 |
Why?
|
| Gels | 1 | 2007 | 5 | 0.020 |
Why?
|
| Lysosomes | 1 | 2007 | 14 | 0.020 |
Why?
|
| Proteasome Inhibitors | 1 | 2007 | 10 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2007 | 32 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 38 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 45 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2004 | 3 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 282 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 571 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 10 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2001 | 8 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2001 | 7 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2001 | 13 | 0.010 |
Why?
|
| Insect Proteins | 1 | 2000 | 1 | 0.010 |
Why?
|
| Cdh1 Proteins | 1 | 2000 | 1 | 0.010 |
Why?
|
| Drosophila | 1 | 2000 | 3 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2000 | 9 | 0.010 |
Why?
|
| Cell Division | 1 | 2000 | 40 | 0.010 |
Why?
|
| Base Sequence | 1 | 2000 | 65 | 0.010 |
Why?
|